Despite previous issues with on-target off-tumor toxicity when ErbB family members have been targeted using CAR T-cell immunotherapy,17 safety of the intratumoral approach described here has been robustly demonstrated at doses of up to 1×109 T4+ cells. The gene discussed is EGFR; the disease is neoplasm.